Add to ORKGProvides an overview of Australia's Pharmaceutical Benefits Scheme and its consideration of both comparative effectiveness and cost-effectiveness in deciding on drug subsidies. Outlines its framework, structure, and impact on policy and practice
Background: The Pharmaceutical Benefits Scheme (PBS) is Australia's national drug subsidy program. T...
BACKGROUND: The Pharmaceutical Benefits Scheme (PBS) is Australia's national drug subsidy program. T...
The Pharmaceutical Benefits Advisory Committee (PBAC) plays an important role in controlling the dru...
Australia has had a government subsi dized universal system of pharmaceutical provision for 50 years...
Objective: To analyze the relative influence of factors in decisions for public insurance coverage o...
Objectives: The aim of this study was to examine submissions made to the Pharmaceutical Benefits Adv...
AbstractBackgroundAssessments of the comparative clinical (and cost) effectiveness of new medicines ...
Background: Access to 'high-cost medicines' under Australia's Pharmaceutical Benefits Scheme (PBS) i...
Published online: 27 January 2016In Australia, the Pharmaceutical Benefits Advisory Committee (PBAC)...
A concern to contain the costs of providing equality of access to prescription medicines while prese...
Background: The hurdle of cost effectiveness for the selection and reimbursement of drugs in Austral...
THE FUNDING CRISIS in the Pharmaceutical Benefits Scheme poses the greatest threat to its existence ...
AbstractObjectivesIn light of the current debate on the use value and potential impact of comparativ...
Overview: Poor implementation of a policy to get better value for PBS spending is costing government...
This paper considers the role of economic evaluation of health care technologies in Australia and it...
Background: The Pharmaceutical Benefits Scheme (PBS) is Australia's national drug subsidy program. T...
BACKGROUND: The Pharmaceutical Benefits Scheme (PBS) is Australia's national drug subsidy program. T...
The Pharmaceutical Benefits Advisory Committee (PBAC) plays an important role in controlling the dru...
Australia has had a government subsi dized universal system of pharmaceutical provision for 50 years...
Objective: To analyze the relative influence of factors in decisions for public insurance coverage o...
Objectives: The aim of this study was to examine submissions made to the Pharmaceutical Benefits Adv...
AbstractBackgroundAssessments of the comparative clinical (and cost) effectiveness of new medicines ...
Background: Access to 'high-cost medicines' under Australia's Pharmaceutical Benefits Scheme (PBS) i...
Published online: 27 January 2016In Australia, the Pharmaceutical Benefits Advisory Committee (PBAC)...
A concern to contain the costs of providing equality of access to prescription medicines while prese...
Background: The hurdle of cost effectiveness for the selection and reimbursement of drugs in Austral...
THE FUNDING CRISIS in the Pharmaceutical Benefits Scheme poses the greatest threat to its existence ...
AbstractObjectivesIn light of the current debate on the use value and potential impact of comparativ...
Overview: Poor implementation of a policy to get better value for PBS spending is costing government...
This paper considers the role of economic evaluation of health care technologies in Australia and it...
Background: The Pharmaceutical Benefits Scheme (PBS) is Australia's national drug subsidy program. T...
BACKGROUND: The Pharmaceutical Benefits Scheme (PBS) is Australia's national drug subsidy program. T...
The Pharmaceutical Benefits Advisory Committee (PBAC) plays an important role in controlling the dru...